Vasopressin V1a and V1b receptor modulators: a patent review (2012 – 2014)

Bibliography

• Thibonnier M, Berti-Mattera LN, Dulin N, et al. Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Prog Brain Res 1998;119:147-61
   PubMed Web of Science ®Google Scholar
• Brownstein MJ, Russell JT, Gainer HT. Synthesis, transport, and release of posterior pituitary hormones. Science 1980;207:373-8
   PubMed Web of Science ®Google Scholar
• Feldman RS, Meyer JS, Quenzer LF. Principles of neuropsychopharmacology. Sinauer Associates 1997
   Google Scholar
• Lebl M, Jošt K, Brtník F. Tables of Analogs. In Handbook of neurohypophysial hormone analogs. CRC Press, Inc 1987;1(2):127-267
   Google Scholar
• Yang Y, Li H, Ward R, et al. Novel oxytocin receptor agonists and antagonists: a patent review (2002-2013). Expert Opin Ther Pat 2014;24:29-46
   PubMed Web of Science ®Google Scholar
• Tsukamoto I. Recent patenting activities in the discovery and development of vasopressin V2 receptor agonists. Expert Opin Ther Pat 2012;22:579-86
   PubMed Web of Science ®Google Scholar
• Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J Endocrinol 1998;156:223-9
   PubMed Web of Science ®Google Scholar
• Terrillon S, Durroux T, Mouillac B, et al. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 2003;17:677-91
   PubMed Web of Science ®Google Scholar
• Devost D, Zingg HH. Homo- and hetero-dimeric complex formations of the human oxytocin receptor. J Neuroendocrinol 2004;16:372-7
   PubMed Web of Science ®Google Scholar
• Murat B, Devost D, Andrés M, et al. V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH. Mol Endocrinol 2012;26:502-20
   PubMed Web of Science ®Google Scholar
• Hunyady L, Vauquelin G, Vanderheyden P. Agonist induction and conformational selection during activation of a G-protein-coupled receptor. Trends in Pharm Sci 2003;24:81-6
   PubMed Web of Science ®Google Scholar
• Koshimizu TA, Nasa Y, Tanoue A, et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA 2006;103:7807-12
   PubMed Web of Science ®Google Scholar
• Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 1993;103:1241-5
   PubMed Web of Science ®Google Scholar
• Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev 1988;68:1248-84
   PubMed Web of Science ®Google Scholar
• Hasser EM, Bishop VS. Reflex effect of vasopressin after blockade of V1 receptors in the area postrema. Circ Res 1990;67:265-71
   PubMed Web of Science ®Google Scholar
• Guillon G, Trueba M, Joubert D, et al. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology 1995;136:1285-95
   PubMed Web of Science ®Google Scholar
• Morel A, O’Carroll AM, Brownstein MJ, et al. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 1992;356:523-6
   PubMed Web of Science ®Google Scholar
• Hiroyama M, Aoyagi T, Fujiwara Y, et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol Endocrinol 2007;21:247-58
   PubMed Web of Science ®Google Scholar
• Inoue T, Nonoguchi H, Tomita K. Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. Cardiovasc Res 2001;51:470-80
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Mattson DL, Gross V, et al. Control of renal medullary blood flow by vasopressin V1 and V2 receptors. Am J Physiol Regul Integr Comp Physiol 1995;269:R193-200
   PubMed Web of Science ®Google Scholar
• Morris JF. VP/OT in Handbok of biologically active peptides. editor. Kastin A. Elsevier; Amsterdam: 2013. p. 975-81
   Google Scholar
• Memetimin H, Izumi Y, Nakayama Y, et al. Low pH stimulates vasopressin V2 receptor promoter activity and enhances downregulation induced by V1a receptor stimulation. Am J Physiol Renal Physiol 2009;297:F620-8
   PubMed Web of Science ®Google Scholar
• Aoyagi T, Izumi Y, Hiroyama M, et al. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol 2008;295:F100-7
   PubMed Web of Science ®Google Scholar
• Laycock J, Meeran K. The Pituitary Gland (2): The Posterior Lobe (Neurohypophysis). Integrative endocrinology. John Wiley & Sons; Oxford: 2012:89-109
   Google Scholar
• Barberis C, Tribollet E. Vasopressin and oxytocin receptors in the central nervous system. Crit Rev Neurobiol 1996;10:119-54
   PubMed Web of Science ®Google Scholar
• Israel S, Lerer E, Shalev I, et al. Molecular genetic studies of the arginine vasopressin 1a receptor (AVPR1a) and the oxytoci receptor (OXTR) in human behaviour: from autism to altruism with some notes in between. Prog Brain Res 2008;170:435-49
   PubMed Web of Science ®Google Scholar
• Sanbe A, Takagi N, Fujiwara Y, et al. A Alcohol preference in mice lacking the Avpr1a vasopressin receptor. Am J Physiol Regul Integr Comp Physiol 2008;294:R1482-90
   PubMed Web of Science ®Google Scholar
• Lolait SJ, O’Carroll AM, Mahan LC, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 1995;92:6783-7
   PubMed Web of Science ®Google Scholar
• Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993;14:76-122
   PubMed Web of Science ®Google Scholar
• Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477-501
   PubMed Web of Science ®Google Scholar
• de Winter RF, van Hemert AM, Derijk RH, et al. Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003;28:140-7
   PubMed Web of Science ®Google Scholar
• Dinan TG, O’Brien S, Lavelle E, et al. Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med 2004;34:169–72
   PubMed Web of Science ®Google Scholar
• Serradeil-Le Gal C, Wagnon JIII, Tonnerre B, et al. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev 2005;11:53-68
   PubMedGoogle Scholar
• Iijima M, Chaki S. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:622-7
   PubMed Web of Science ®Google Scholar
• Caldwell HK, Wersinger SR, Young WS. Advances in vasopressin and oxytocin. The role of the vasopressin V1b receptor in aggression and other social behaviours. In: Landgraf R, Leumann ID. editors. Advances in Vasopressin and Oxytocin - From Genes to Behaviour to Disease. Elsevier, Amsterdam;2008:65-72
   Google Scholar
• DeVito LM, Konigsberg R, Lykken C, et al. Vasopressin 1b receptor knock-out impairs memory for temporal order. J Neurosci 2009;29:2676-83
   PubMed Web of Science ®Google Scholar
• Lolait SJ, O’Carroll AM, Mahan LC, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 1995;92:6783-7
   PubMed Web of Science ®Google Scholar
• Folny V, Raufaste D, Lukovic L, et al. Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas. Am J Physiol Endocrinol Metab 2003;285:E566-76
   PubMed Web of Science ®Google Scholar
• Koshimizu T, Nakamura K, Egashira N, et al. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 2012;92:1813-64
   PubMed Web of Science ®Google Scholar
• Ferring BV. Peptidic vasopressin receptor agonists. US8148319; 2012
   Google Scholar
• Ferring BV. Use of peptidic vasopressin receptor agonists. US8222202; 2012
   Google Scholar
• O’Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002;359:1209-10
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal hemorrhage. Aliment Pharmacol Ther 2003;17:53-64
   PubMed Web of Science ®Google Scholar
• Miano TA, Pharm D, Crouch MA. Evolving role of vasopressin in the treatment of cardiac arrest. Pharmacotherapy 2006;6:828-39
   Web of Science ®Google Scholar
• Bauer SR, Pharm D, Lam SW. Arginine vasopressin for the treatment of septic shock in adults. Pharmacotherapy 2010;10:1057-71
   Web of Science ®Google Scholar
• Barlow M. Vasopressin. Emerg Med 2002;14:304-14
   PubMedGoogle Scholar
• Augustin S, Gonzalez A, Genesca J. Acute esophageal variceal bleeding: current strategies and new perspectives. World J Hepatol 2010;2:261-74
   PubMedGoogle Scholar
• Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-8
   PubMed Web of Science ®Google Scholar
• Bernadich C, Bandi JC, Melin P, et al. Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 1998;27:351-6
   PubMed Web of Science ®Google Scholar
• Ryckwaert F, Virsolvy A, Fort A, et al. Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med 2009;37:876-81
   PubMed Web of Science ®Google Scholar
• O’Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002;359:1209-10
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche Ag. Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists. US0079333; 2013
   Google Scholar
• Hoffmann-La Roche Ag. Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists. WO050334; 2013
   Google Scholar
• Hoffmann-La Roche, Inc. Arylcyclohexylethers of dihydrotetraazabenzoazulenes. US8461152; 2013
   Google Scholar
• Hoffmann-La Roche, Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes. US8492376; 2013
   Google Scholar
• Ali F, Guglin M, Vaitkevicius P, et al. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007;67:847-58
   PubMed Web of Science ®Google Scholar
• Vantia Ltd. Vasopressin V1a antagonists. US8202858; 2012
   Google Scholar
• Ferring BV. Benzamide derivatives as oxytocin agonists and vasopressin antagonists. EP1449844A1; 2004
   Google Scholar
• Akerlund M, Melin P, Maggi M. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Adv Exp Med Biol 1995;395:595-600
   PubMedGoogle Scholar
• Abbott Gmbh & Co. Kg. Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands. US8431567; 2013
   Google Scholar
• AbbVie Deutschland GmbH & Co. KG. 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases. US8546401; 2013
   Google Scholar
• AbbVie Deutschland GmbH & Co. KG. Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses. US8629148; 2014
   Google Scholar
• Abbott Gmbh & Co. Kg. Substituted oxindole derivatives and their use as vasopressin receptor ligands. US0322809; 2012
   Google Scholar
• Abbott Gmbh & Co. Kg. Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them. US8580842; 2013
   Google Scholar
• AbbVie Deutschland GmbH & Co. KG. Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases. US8703774; 2014
   Google Scholar
• AbbVie Deutschland GmbH & Co. KG. Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses. US8703775; 2014
   Google Scholar
• Porsolt RD, Anton G, Blavet N, et al. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978;47:379-91
   PubMed Web of Science ®Google Scholar
• Kirchhoff VD, Nguyen HT, Soczynska JK, et al. Discontinued psychiatric drugs in 2008. Expert Opin Investig Drugs 2009;18:1431-43
   PubMed Web of Science ®Google Scholar
• Griebel G, Beeské S, Stahl SM. The vasopressin V1b receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2012;73:1403-11
   PubMed Web of Science ®Google Scholar
• Arban R. V1b receptors: new probes for therapy. Endocrinology 2007;148:4133-5
   PubMed Web of Science ®Google Scholar
• Chini B, Manning M. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. Biochem Soc Trans 2007;35:737-41
   PubMed Web of Science ®Google Scholar
• Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology 2006;105:599-612
   PubMed Web of Science ®Google Scholar
• Gross PA, Wagner A, Decaux G. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. Kidney Int 2011;80:594-600
   PubMed Web of Science ®Google Scholar
• Manning M, Misicka A, Olma A, et al. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 2012;24:609-28
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Keserü GM, Leeson PD, et al. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov 2014;13:105-21
   PubMed Web of Science ®Google Scholar
• Manning M, Stoev S, Chini B, et al. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 2008;170:473-512
   PubMed Web of Science ®Google Scholar
• Boss V, Talpade DJ, Murphy TJ. Induction of NFAT-mediated transcription by Gq-coupled receptors in lymphoid and non-lymphoid cells. J Biol Chem 1996;271:10429-32
   PubMed Web of Science ®Google Scholar
• Dekanski J. The quantitative assay of vasopressin. Br J Pharmacol 1952;7:567-72
   Web of Science ®Google Scholar
• Tahara A, Saito M, Sugimoto T, et al. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol 1998;125:1463-70
   PubMed Web of Science ®Google Scholar
• Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-108
   PubMed Web of Science ®Google Scholar